Clinical Trial Update: Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety, tolerability, patient satisfaction, and cost of 16.5% subcutaneous immunoglobulin (Cutaquig) for primary and secondary immunodef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency
• Immunodeficiency Disease

Drugs mentioned

• Cutaquig (immunoglobulin G (human) for subcutaneous administration)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Primary Immunodeficiency Disease, Secondary Immunodeficiency | Phase 4 | Status: UNKNOWN